These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 34036420)

  • 1. Prognostic value of response evaluation based on breast MRI after neoadjuvant treatment: a retrospective cohort study.
    Bitencourt AGV; Pires BS; Calsavara VF; Negrão EMS; Souza JA; Graziano L; Guatelli CS; Makdissi FB; Sanches SM; Tavares MC; Osório CABT; De Brot M; Marques EF; Chojniak R
    Eur Radiol; 2021 Dec; 31(12):9520-9528. PubMed ID: 34036420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
    Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
    Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
    Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
    Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
    Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can breast MRI predict pathologic response following neoadjuvant chemotherapy for breast cancer? A retrospective cohort study.
    Kwak L; Santa-Maria C; Di Carlo P; Mullen LA; Myers KS; Oluyemi E; Panigrahi B; Rossi J; Ambinder EB
    Clin Imaging; 2023 Sep; 101():105-112. PubMed ID: 37327550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.
    van Ramshorst MS; Loo CE; Groen EJ; Winter-Warnars GH; Wesseling J; van Duijnhoven F; Peeters MTV; Sonke GS
    Breast Cancer Res Treat; 2017 Jul; 164(1):99-106. PubMed ID: 28432515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype.
    Ko ES; Han H; Han BK; Kim SM; Kim RB; Lee GW; Park YH; Nam SJ
    Korean J Radiol; 2015; 16(5):986-95. PubMed ID: 26357493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes.
    Kim J; Han BK; Ko EY; Ko ES; Choi JS; Park KW
    Eur Radiol; 2022 Jun; 32(6):4056-4066. PubMed ID: 34989844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast radiologic complete response is associated with favorable survival outcomes after neoadjuvant chemotherapy in breast cancer.
    Woo J; Ryu JM; Jung SM; Choi HJ; Lee SK; Yu J; Lee JE; Kim SW; Nam SJ; Chae BJ
    Eur J Surg Oncol; 2021 Feb; 47(2):232-239. PubMed ID: 33213958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy.
    Negrão EMS; Souza JA; Marques EF; Bitencourt AGV
    Eur J Radiol; 2019 Nov; 120():108701. PubMed ID: 31610321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?
    Thompson BM; Chala LF; Shimizu C; Mano MS; Filassi JR; Geyer FC; Torres US; de Mello GGN; da Costa Leite C
    Eur Radiol; 2022 Mar; 32(3):1663-1675. PubMed ID: 34716780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Choi JS; Ko ES; Ko EY; Han BK; Nam SJ
    Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer.
    Sener SF; Sargent RE; Lee C; Manchandia T; Le-Tran V; Olimpiadi Y; Zaremba N; Alabd A; Nelson M; Lang JE
    J Surg Oncol; 2019 Nov; 120(6):903-910. PubMed ID: 31400007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
    Goorts B; Dreuning KMA; Houwers JB; Kooreman LFS; Boerma EG; Mann RM; Lobbes MBI; Smidt ML
    Breast Cancer Res; 2018 Apr; 20(1):34. PubMed ID: 29669584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
    De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
    Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy.
    Asaoka M; Narui K; Suganuma N; Chishima T; Yamada A; Sugae S; Kawai S; Uenaka N; Teraoka S; Miyahara K; Kawate T; Sato E; Nagao T; Matsubara Y; Gandhi S; Takabe K; Ishikawa T
    Eur J Surg Oncol; 2019 Dec; 45(12):2289-2294. PubMed ID: 31787153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with radiologic-pathologic discordance in magnetic resonance imaging after neoadjuvant chemotherapy for breast cancer.
    Kwon MR; Chu J; Kook SH; Kim EY
    Clin Imaging; 2022 Sep; 89():1-9. PubMed ID: 35654000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Post Neoadjuvant Axillary Response Using a Novel Convolutional Neural Network Algorithm.
    Ha R; Chang P; Karcich J; Mutasa S; Van Sant EP; Connolly E; Chin C; Taback B; Liu MZ; Jambawalikar S
    Ann Surg Oncol; 2018 Oct; 25(10):3037-3043. PubMed ID: 29978368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.